Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

Company Overview

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Key Stats

• Today's Range: $2.79 to $2.89
• 50-Day Range: $2.31 to $3.03
• 52-Week Range: $1.05 to $3.31
• Volume: 615,771 shs
• Average Volume: 2.87 million shs
• Market Capitalization: $776.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.29
• Consensus Rating: Buy

Taysha Gene Therapies Stock Analysis - MarketRank™

Taysha Gene Therapies scored higher than 66% of companies evaluated by MarketBeat, and ranked 344th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Taysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Taysha Gene Therapies has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Taysha Gene Therapies is -8.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Taysha Gene Therapies is -8.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Taysha Gene Therapies has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.50% of the float of Taysha Gene Therapies has been sold short.

Short Interest Ratio / Days to Cover

Taysha Gene Therapies has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Taysha Gene Therapies has recently decreased by 13.08%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Taysha Gene Therapies does not currently pay a dividend.

Dividend Growth

Taysha Gene Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.50% of the float of Taysha Gene Therapies has been sold short.

Short Interest Ratio / Days to Cover

Taysha Gene Therapies has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Taysha Gene Therapies has recently decreased by 13.08%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.20

News Sentiment

Taysha Gene Therapies has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,062,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.78% of the stock of Taysha Gene Therapies is held by insiders.

Percentage Held by Institutions

77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TSHA Stock Analysis - Frequently Asked Questions

How have TSHA shares performed this year?

Taysha Gene Therapies' stock was trading at $1.73 on January 1st, 2025. Since then, TSHA shares have increased by 63.3% and is now trading at $2.8250.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.02. The company had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.61 million. Taysha Gene Therapies had a negative trailing twelve-month return on equity of 78.44% and a negative net margin of 1,144.97%.
Read the conference call transcript.

When did Taysha Gene Therapies IPO?

Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager.

Who are Taysha Gene Therapies' major shareholders?

Top institutional shareholders of Taysha Gene Therapies include Octagon Capital Advisors LP (5.87%), Jefferies Financial Group Inc. (4.80%), Adage Capital Partners GP L.L.C. (2.25%) and Tybourne Capital Management HK Ltd. (1.91%). Insiders that own company stock include RA Session II, Paul B Manning, Sean P Nolan, Kamran Alam and Sukumar Nagendran.
View institutional ownership trends.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Taysha Gene Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/29/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSHA
• CIK: 1806310
• Web: www.tayshagtx.com
• Phone: 214-612-0000
• Fax: N/A
• Employees: 180
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Taysha Gene Therapies: $8.29
• High Price Target: $11.00
• Low Price Target: $6.00
• Potential Upside/Downside: +191.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$89.30 million
• Net Margins: -1,144.97%
• Pretax Margin: -1,144.97%
• Return on Equity: -78.44%
• Return on Assets: -44.82%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 12.48
• Quick Ratio: 12.48

Sales & Book Value

• Annual Sales: $8.10 million
• Price / Sales: 95.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.91 per share
• Price / Book: 3.13

Miscellaneous

• Outstanding Shares: 272,795,000
• Free Float: 262,483,000
• Market Cap: $776.10 million
• Optionable: Optionable
• Beta: 0.98